Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

US FDA Outlines Biosimilar First Interchangeability Policy … In A Memo

Nov 13 2023

• By Derrick Gingery

Humira 40mg — The memo on Humira biosimilars reveals some interchangeable exclusivity policies but there is more unpacking to do • Source: Shutterstock

Related Content

Biosimilars: US FDA Developing Guidance For First Interchangeable Exclusivity

Nov 18 2020

Interchangeable Exclusivity: Pfizer To Rival Boehringer On Humira Biosimilar After US FDA Decision

Oct 10 2023

The Immortal Humira? In Huge Test For US Biosimilar Policy, Brand May Still Have Edge

Jan 31 2023

Biosimilars: US FDA Developing Guidance For First Interchangeable Exclusivity

Nov 20 2020

FDA Decision On Interchangeable Exclusivity Allows Pfizer To Rival Boehringer On Adalimumab

Oct 09 2023

AbbVie Hails Humira’s Resistance To US Competition

Jul 28 2023

Related Companies

Boehringer Ingelheim GmbH

AbbVie Inc.

Pfizer Inc.

Additional Topics

United States Biosimilars Regulation Legal Issues FDA BioPharmaceutical

More from Biosimilars

More from Products

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window